Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Free Cash Flow (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Free Cash Flow for 6 consecutive years, with -$22.2 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 30.48% to -$22.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$112.4 million through Dec 2025, up 19.15% year-over-year, with the annual reading at -$112.4 million for FY2025, 19.15% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$22.2 million at Caribou Biosciences, up from -$23.8 million in the prior quarter.
  • The five-year high for Free Cash Flow was $20.3 million in Q1 2021, with the low at -$38.1 million in Q1 2024.
  • Average Free Cash Flow over 5 years is -$24.2 million, with a median of -$24.6 million recorded in 2022.
  • The sharpest move saw Free Cash Flow plummeted 210.37% in 2022, then soared 35.53% in 2025.
  • Over 5 years, Free Cash Flow stood at -$23.2 million in 2021, then dropped by 9.76% to -$25.5 million in 2022, then decreased by 27.15% to -$32.4 million in 2023, then increased by 1.77% to -$31.9 million in 2024, then soared by 30.48% to -$22.2 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$22.2 million, -$23.8 million, and -$29.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.